Callisto Pharmaceuticals Inc. - KAL

Callisto Pharmaceuticals Inc. (KAL)
Coverage: October 1, 2005 - April 1, 2006
Featured: October 1, 2005

Latest Newsletter Editions

Wed, Sep 6, 2006 @ 02:09 pm
Wake Me Up When September Ends as my memory rests but never forgets what I lost wake me up when september ends Greenday from the song Wake Me Up When September Ends The lyrics from Greenday's hit song are worth remembering this time of year. Why? - did you know September is historically the worst month...
Tue, Mar 21, 2006 @ 01:03 pm
Bad Toys (OTC BB: BTYH) Announces Contract Extension Bad Toys was out with a contract extension announcement for its Southland Health Care subsidiary. Southland is the entity all of us shareholders hope to see trade on the AMEX or NASDAQ Small Cap on a stand alone basis later this year. The contract...
Tue, Mar 7, 2006 @ 01:03 pm
Callisto Pharmacueticals (AMEX: KAL); Sets Sites on Potential Colon Cancer Therapy Callisto in on the verge of developing a myriad of cancer therapies, any or all of whom could put this stock at considerably higher levels. Consider there are only about 40 million shares issued and outstanding. At the...
Tue, Feb 28, 2006 @ 01:02 pm
Callisto Pharmaceuticals (AMEX: KAL): New Highs Should Be Imminent KAL shared some news with investors today post close. The news is extremely robust, and I believe could take the stock to new post OTC Journal coverage highs. We will see tomorrow and over the course of the next few days. Fundamentally...
Sun, Feb 19, 2006 @ 09:02 am
Interest Rates and Oil: A FED Led Market Doldrum 2006 kicked off with a Bang. On January 3rd, someone flipped the micro cap stock switch, and we enjoyed a couple of breakouts early in the year. The second half of 2005 was brutal, so I guess we were entitled to a rebound. It's the first time in many...

Click Here For More Newsletters on KAL


Latest Blog Entries


Quote Data

Last Trade: Bid: 0.0000
Last Size: 0 Ask: 0.0000
Trade Time: Bid x Ask Size:
Change: +0.0000 (+0.00%) Day's Range: 0.00 - 0.00
Prev Close: 0.0000 52wk Range: 0.00 - 0.00
Open: 0.0000 P/E (ttm):
Volume: 0 EPS (ttm):
spacer [Chart]

Business Summary

Callisto Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development of drugs for the treatment of blood cancers and related diseases, including acute lymphoblastic leukemia, acute myelogenous leukemia, relapsed or refractory multiple myeloma, and osteolytic disease. Its lead drug candidate, L-Annamycin, is a liposomal drug from the anthracycline family, which completed Phase I/IIa clinical trial in relapsed or refractory leukemia patients. The company’s other product includes Atiprimod, a small molecule oral drug, which is in a Phase I/IIa clinical trial in relapsed or refractory multiple myeloma patients. Callisto Pharmaceuticals developed Guanilib for gastrointestinal inflammation; and a monoclonal antibody that is being explored as a biodefensive agent against staphylococcal and streptococcal bioweapons. It also develops a drug preclinically for treatment of inflammatory bowel disease. In addition, the company has a license agreement with the University of Texas M.D. Anderson Cancer Center to manufacture and sell anticancer compounds, called Degrasyns, a class of tyrphostins that have a anticancer mechanism-of-action to degrade proteins involved in tumor cell proliferation and survival. The company was founded in 1996 and is headquartered in New York City.


Callisto Pharmaceuticals has paid MarketByte LLC a fee of $30,000 for coverage of the company. In addition, Trilogy Capital Partners has granted MarketByte LLC 179,332 warrants, convertible into free trading shares, with an exercise price of $1.03.

Recent News Headlines